Salon Media Group, Inc. (OTCMKTS:SLNM) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Spear Point Capital Management Llc. has picked up 190,154,289 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Spear Point Capital Management Llc. to a total of 190,154,289 representing a 69.05% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized and Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Salon Media Group, Inc. (OTCMKTS:SLNM)’s key stats reveals a current market capitalization of 5.72 million based on 76.27 million shares outstanding and a price at last close of $0.100 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-04, Hambrecht picked up 10,261,429 at a purchase price of $0.35. This brings their total holding to 27,174,322 as of the date of the filing.
On the sell side, the most recent transaction saw Warnock unload 10,261,429 shares at a sale price of $0.35. This brings their total holding to 34,878,281.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Salon Media Group, Inc. (OTCMKTS:SLNM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Svlsf V, Llc. is Buying Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that Svlsf V, Llc. has picked up 2,857,667 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,857,667 representing a 15.3% stake in the company.
For those not familiar with the company, Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties.
A glance at Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)’s key stats reveals a current market capitalization of 23.71 million based on 18.65 million shares outstanding and a price at last close of $1.23 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-06-30, George picked up 12,422 at a purchase price of $12.00. This brings their total holding to 90,764 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Huckleberry Investments Llp. Picked Up Jrjr33 Inc. (NYSEMKT:JRJR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Jrjr33 Inc. (NYSEMKT:JRJR) reported that Huckleberry Investments Llp. has picked up 3,441,232 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Huckleberry Investments Llp. to a total of 3,441,232 representing a 8.75% stake in the company.
For those not familiar with the company, JRjr33, Inc. (JRJR), formerly CVSL Inc., offers a platform of direct-to-consumer brands. The Company operates through the segments, which include Gourmet Food, Nutritional and Wellness, Home Decor, Publishing and Printing, and Other. The Gourmet Food Products segment consists of operations related to the production and sale of hand-crafted spices, oils and other food products from around the world. The Home Decor segment consists of operations related to the production and sale of premium hand-crafted baskets, and the selling of products for the home, including pottery, cleaning, health, beauty, home, outdoor and customizable vinyl expressions for display. The Nutritionals and Wellness segment consists of operations related to the selling of nutritional supplements and skin care products.
A glance at Jrjr33 Inc. (NYSEMKT:JRJR)’s key stats reveals a current market capitalization of 31.92 million based on 39.38 million shares outstanding and a price at last close of $0.779 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-16, Randall picked up 4,890 at a purchase price of $1.16. This brings their total holding to 27,000 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Jrjr33 Inc. (NYSEMKT:JRJR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Just Picked Up Ocular Therapeutix Inc. (NASDAQ:OCUL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocular Therapeutix Inc. (NASDAQ:OCUL) reported that Svlsf V, Llc. has picked up 1,605,207 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 1,605,207 representing a 6.5% stake in the company.
For those not familiar with the company, Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug.
A glance at Ocular Therapeutix Inc. (NASDAQ:OCUL)’s key stats reveals a current market capitalization of 198.42 million based on 28.76 million shares outstanding and a price at last close of $6.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-15, Sawhney picked up 45,300 at a purchase price of $7.85. This brings their total holding to 677,390 as of the date of the filing.
On the sell side, the most recent transaction saw Fortune unload 9,470 shares at a sale price of $17.16. This brings their total holding to 112,060.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocular Therapeutix Inc. (NASDAQ:OCUL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) reported that Svlsf V, Llc. has picked up 2,579,490 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 2,579,490 representing a 26.6% stake in the company.
For those not familiar with the company, KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
A glance at Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)’s key stats reveals a current market capitalization of 70.68 million based on 9.93 million shares outstanding and a price at last close of $7.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-14, Cha picked up 7,364 at a purchase price of $5.00. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Renzi unload 10,000 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Sino Agro Food Inc. (OTCMKTS:SIAF) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sino Agro Food Inc. (OTCMKTS:SIAF) reported that Forsakringsaktiebolaget Avanza Pension has picked up 2,778,385 of common stock as of 2017-02-06.
The acquisition brings the aggregate amount owned by Forsakringsaktiebolaget Avanza Pension to a total of 2,778,385 representing a 12.95% stake in the company.
For those not familiar with the company, Sino Agro Food, Inc. is an agriculture technology and natural food holding company. The Company acquires and maintains equity stakes in a portfolio of companies to produce, distribute, market and sell protein food, and produce, primarily seafood and cattle. It provides consulting and services to joint venture partners to construct and operate food businesses, producing wholesale fish and cattle. It operates in five segments: Fishery Development Division operated by Capital Award, Inc. and Jiang Men City A Power Fishery Development Co., Limited; HU Plantation Division operated by Jiang Men City Heng Sheng Tai Agriculture Development Co., Limited; Organic Fertilizer and Bread Grass Division operated by Qinghai Sanjiang A Power Agriculture Co., Limited and Qinghai Zhong He Meat Products Co., Limited, among others; Cattle Farm Development Division operated by Jiang Men City Hang Mei Cattle Farm Development Co. Limited and Macau Eiji Company Limited, and Corporate and Others Division.
A glance at Sino Agro Food Inc. (OTCMKTS:SIAF)’s key stats reveals a current market capitalization of 77.24 million based on 21.46 million shares outstanding and a price at last close of $3.60 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-01-21, Tiusanen picked up 2,500 at a purchase price of $9.14. This brings their total holding to 5,000 as of the date of the filing.
On the sell side, the most recent transaction saw Sandberg unload 10,000 shares at a sale price of $4.85. This brings their total holding to 76,949.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sino Agro Food Inc. (OTCMKTS:SIAF) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Vycor Medical Inc. (OTCMKTS:VYCO) Shares
January has been a big month for biotech, with the JP Morgan conference dominating the start of the year. The conference traditionally brings about a host of deals and new buys, and this latest Vycor pick up suggests there’s plenty more to come before the end of the month.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vycor Medical Inc. (OTCMKTS:VYCO) reported that Fountainhead Capital Management Ltd. has picked up 9,733,832 of common stock as of 2017-01-20.
The acquisition brings the aggregate amount owned by Fountainhead Capital Management Ltd. to a total of 9,733,832 representing a 55.74% stake in the company.
For those not familiar with the company, Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company operates through two segments: Vycor Medical, which focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals, and NovaVision, which focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage. The Company designs, develops and markets neurological medical devices and therapies. The Company operates in the United States and Europe. Vycor Medical’s product Vycor Medical’s ViewSite Brain Access System (VBAS) is a next generation retraction and access system. VBAS is a disposable product that can be used with microscopic, endoscopic and neuro-navigation systems.
A glance at Vycor Medical Inc. (OTCMKTS:VYCO)’s key stats reveals a current market capitalization of 2.82 million based on 11.22 million shares outstanding and a price at last close of $0.250 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-12-31, Fountainhead picked up 8,380 at a purchase price of $1.79. This brings their total holding to 4,366,844 as of the date of the filing.
On the sell side, the most recent transaction saw Bronsther unload 6,241 shares at a sale price of $2.75. This brings their total holding to 18,216.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vycor Medical Inc. (OTCMKTS:VYCO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.